McCredie Margaret R E, Sharples Katrina J, Paul Charlotte, Baranyai Judith, Medley Gabriele, Jones Ronald W, Skegg David C G
Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.
Lancet Oncol. 2008 May;9(5):425-34. doi: 10.1016/S1470-2045(08)70103-7. Epub 2008 Apr 11.
The invasive potential of cervical intraepithelial neoplasia 3 (CIN3; also termed stage 0 carcinoma) has been poorly defined. At the National Women's Hospital, Auckland, New Zealand, treatment of CIN3 was withheld from a substantial number of women between 1965 and 1974 as part of an unethical clinical study. The resulting variation in management allows comparison of the long-term risk of invasive cancer of the cervix in women whose lesion was minimally disturbed with those who had adequate initial treatment followed by conventional management. We aimed to estimate the long-term risk of invasive cancer in these two groups of women. A judicial inquiry referred for independent clinical review in 1988 all women for whom there remained doubt about the adequacy of their management.
Between February, 2001, and December, 2004, medical records, cytology, and histopathology were reviewed for all women with CIN3 diagnosed between 1955 and 1976, whose treatment was reviewed by judicial inquiry and whose medical records could be located, and linkages were done with cancer and death registers and electoral rolls. To take into account the probability that the CIN3 lesion had been completely removed, we classified adequacy of treatment by type of procedure, presence of CIN3 at the excision margin, and subsequent cytology. The primary outcome was cumulative incidence of invasive cancer of the cervix or vaginal vault. Follow-up continued until death or Dec 31, 2000, whichever came first. Analyses accounted for procedures during follow-up.
1229 women whose treatment was reviewed by the judicial inquiry in 1987-88 were included. Of these, 48 records (4%) could not be located and 47 women (4%) did not meet the inclusion criteria. At histopathological review, a further 71 (6% of 1134) women were excluded because the review diagnosis was not CIN3. We identified outcomes in the remaining 1063 (86% of 1229) women diagnosed with CIN3 at the hospital in 1955-76. In 143 women managed only by punch or wedge biopsy, cumulative incidence of invasive cancer of the cervix or vaginal vault was 31.3% (95% CI 22.7-42.3) at 30 years, and 50.3% (37.3-64.9) in the subset of 92 such women who had persistent disease within 24 months. However, cancer risk at 30 years was only 0.7% (0.3-1.9) in 593 women whose initial treatment was deemed adequate or probably adequate, and whose treatment for recurrent disease was conventional.
This study provides the most valid direct estimates yet available of the rate of progression from CIN3 to invasive cancer. Women with untreated CIN3 are at high risk of cervical cancer, whereas the risk is very low in women treated conventionally throughout.
宫颈上皮内瘤变3级(CIN3,也称为0期癌)的侵袭潜能一直未得到明确界定。在新西兰奥克兰的国家妇女医院,1965年至1974年间,作为一项不道德临床研究的一部分,大量CIN3患者未接受治疗。这种管理方式的差异使得我们能够比较病变未得到充分处理的女性与接受了充分初始治疗并采用传统管理方式的女性发生宫颈浸润癌的长期风险。我们旨在评估这两组女性发生浸润癌的长期风险。1988年,一项司法调查要求对所有管理方式是否充分存疑的女性进行独立临床审查。
2001年2月至2004年12月期间,我们查阅了1955年至1976年间诊断为CIN3且其治疗情况经过司法调查且病历可找到的所有女性的病历、细胞学和组织病理学资料,并与癌症登记册、死亡登记册和选民名册进行了关联。为了考虑CIN3病变是否已被完全切除的可能性,我们根据手术类型、切除边缘是否存在CIN3以及后续细胞学检查对治疗的充分性进行了分类。主要结局是宫颈或阴道穹窿浸润癌的累积发病率。随访持续至死亡或2000年12月31日,以先到者为准。分析考虑了随访期间的手术情况。
纳入了1987 - 1988年接受司法调查的1229名女性。其中,48份病历(4%)无法找到,47名女性(4%)不符合纳入标准。在组织病理学审查中,由于审查诊断不是CIN3,又有71名女性(1134名中的6%)被排除。我们确定了其余1063名(1229名中的86%)在医院于1955 - 1976年诊断为CIN3的女性的结局。在仅接受穿刺活检或楔形活检的143名女性中,宫颈或阴道穹窿浸润癌的累积发病率在30年时为31.3%(95%CI 22.7 - 42.3),在92名24个月内疾病持续存在的此类女性亚组中为50.3%(37.3 - 64.9)。然而,在593名初始治疗被认为充分或可能充分且复发性疾病采用传统治疗的女性中,30年时患癌风险仅为0.7%(0.3 - 1.9)。
本研究提供了迄今最有效的从CIN3进展为浸润癌发生率的直接估计。未经治疗的CIN3女性患宫颈癌的风险很高,而全程采用传统治疗的女性风险非常低。